Equity Profile

SRPT

Sarepta Therapeutics, Inc.

Health CareBiotechnology$1.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD)....

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and can influence investor sentiment.

N/A

Revenue

Revenue figures are essential to gauge the company's growth and market demand for its therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SRPT Q2-2026 Earnings Preview

Context

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD). With a market cap of $2 billion, Sarepta plays a significant role in the healthcare sector, especially as advancements in gene therapy gain traction.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+1856.93%

Avg Stock Reaction

-2.62%

Last Quarter Recap

In Q1 2026, Sarepta reported an impressive EPS of $3.16, far exceeding estimates, which led to a positive market reaction. However, revenue details were not disclosed, leaving some uncertainty about overall financial health.

Management Promises & Guidance

Continue advancing clinical trials for DMD therapies.
Focus on expanding the pipeline with innovative treatments.
Commit to transparency in future earnings reports.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Sarepta's earnings report, especially after a strong EPS surprise last quarter. However, the lack of revenue guidance raises questions about sustainability.

Bull Case

If Sarepta can demonstrate continued success in its clinical trials and provide positive updates on its pipeline, it could lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations for pipeline progress or reveals disappointing financials, it could trigger a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates will be provided on the clinical trials for DMD therapies?

Investors will closely watch for any positive or negative developments that could impact the company's future revenue potential.

Will there be any guidance on revenue expectations for the upcoming quarters?

Clear revenue guidance is crucial for assessing the company's financial health and growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of recent clinical trial successes, which could lead to higher-than-expected demand for Sarepta's therapies.

Supporting Evidence

Sarepta's recent trial results have shown promise, which could translate into strong revenue growth.

The options market is pricing in a relatively modest move, suggesting that traders may not fully appreciate the potential upside.

Key Risk

If the company announces a significant breakthrough in its clinical trials, it could lead to a major reevaluation of its stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market will weigh the significance of clinical trial outcomes heavily this quarter, as they are pivotal for future revenue.

Bull Confirmed If

Positive updates on clinical trial results for DMD therapies, indicating a strong likelihood of future approvals.

Bear Confirmed If

Failure to provide any meaningful updates on the pipeline or disappointing trial results.

Pre-Earnings Positioning

Options Market

Implied Move

±4.61%

Historical Avg

±5.3%

In line with history

The options market is pricing in a moderate move of about 4.61%, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±4.6% while SRPT has averaged ±5.3% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.7%

30d HV

50.4%

Calls (88K)P/C Ratio: 0.27Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sarepta beats expectations and raises guidance, history suggests a potential average move of +0.82% on the day.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience a muted reaction as investors reassess future growth.

Miss

Should the company miss expectations, history suggests a potential average decline of -12.94% on the day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of clinical trials for DMD therapies.
2Any updates on potential partnerships or collaborations.
3Management's outlook on revenue growth for the next quarter.
4Insights into the competitive landscape for gene therapies.
5Clarification on any regulatory hurdles the company may face.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD)....

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and can influence investor sentiment.

N/A

Revenue

Revenue figures are essential to gauge the company's growth and market demand for its therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SRPT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+1856.93%

Avg Stock Reaction

-2.62%

Last Quarter Recap

Management Promises & Guidance

Continue advancing clinical trials for DMD therapies.
Focus on expanding the pipeline with innovative treatments.
Commit to transparency in future earnings reports.

Expectations

Wall Street Expectations

Bull Case

If Sarepta can demonstrate continued success in its clinical trials and provide positive updates on its pipeline, it could lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations for pipeline progress or reveals disappointing financials, it could trigger a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates will be provided on the clinical trials for DMD therapies?

Investors will closely watch for any positive or negative developments that could impact the company's future revenue potential.

Will there be any guidance on revenue expectations for the upcoming quarters?

Clear revenue guidance is crucial for assessing the company's financial health and growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of recent clinical trial successes, which could lead to higher-than-expected demand for Sarepta's therapies.

Supporting Evidence

Sarepta's recent trial results have shown promise, which could translate into strong revenue growth.

The options market is pricing in a relatively modest move, suggesting that traders may not fully appreciate the potential upside.

Key Risk

If the company announces a significant breakthrough in its clinical trials, it could lead to a major reevaluation of its stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market will weigh the significance of clinical trial outcomes heavily this quarter, as they are pivotal for future revenue.

Bull Confirmed If

Positive updates on clinical trial results for DMD therapies, indicating a strong likelihood of future approvals.

Bear Confirmed If

Failure to provide any meaningful updates on the pipeline or disappointing trial results.

Pre-Earnings Positioning

Options Market

Implied Move

±4.61%

Historical Avg

±5.3%

In line with history

The options market is pricing in a moderate move of about 4.61%, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±4.6% while SRPT has averaged ±5.3% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.7%

30d HV

50.4%

Calls (88K)P/C Ratio: 0.27Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sarepta beats expectations and raises guidance, history suggests a potential average move of +0.82% on the day.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience a muted reaction as investors reassess future growth.

Miss

Should the company miss expectations, history suggests a potential average decline of -12.94% on the day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of clinical trials for DMD therapies.
2Any updates on potential partnerships or collaborations.
3Management's outlook on revenue growth for the next quarter.
4Insights into the competitive landscape for gene therapies.
5Clarification on any regulatory hurdles the company may face.